Close Menu

Seven Bridges: Michael Bigda

Dec 18, 2019

Seven Bridges has named Michael Bigda chief operating officer, filling a vacancy left when previous COO William Moss was elevated to CEO in March. Bigda previously served as senior manager for mergers and acquisitions at industrial tool and consumer hardware manufacturer Stanley Black & Decker. Before that, he was senior VP of operations at Delphi Technology, a maker of software for the medical professional liability market.

More Like This

Sep 18, 2020

Quidel: Robert Bujarski

Quidel has appointed Robert Bujarski as chief operating officer effective Sept. 14. Bujarski had been Quidel's SVP of commercial operations in North America and general counsel since July 2019, SVP of business development from August 2009 through July 2019, and corporate secretary until February 2019.

Sep 17, 2020

iAssay: Edward Strong

Edward Strong has been named scientific director of iAssay, a firm developing an open platform that consolidates utilization of a range of point-of-care tests with a single cloud-connected, handheld reader. Strong, a geneticist, formerly cofounded and served as CEO of MedGenomics, and also served as interim CEO of LifeGenomix.

Sep 17, 2020

Biofidelity: Stephen Miller

Biofidelity has appointed Stephen Miller as chief commercial officer. Miller has held leadership positions at both public and private companies including Precipio, BG Medicine, Thermo Fisher Scientific, and Athena Diagnostics.

Sep 16, 2020

Gravity Diagnostics: Mary Talbott

Gravity Diagnostics has hired Mary Talbott as chief legal secretary and secretary. Talbott has more than 25 years of experience in corporate and private practice and most recently was senior vice president, general counsel, and corporate secretary for Tennant Company. Before that, she was VP, assistant general counsel, and assistant corporate secretary for General Cable. Gravity Dx is a full-service CLIA laboratory based in Covington, Kentucky and provides testing services in infectious diseases, toxicology, and pharmacogenomics.

Sep 15, 2020

Alveo Technologies: Fran Soistman

Fran Soistman has joined the scientific board of Alveo Technologies. He has more than 40 years of experience in the healthcare and managed care sector, including as executive vice president for Aetna. As a member of Alveo's scientific advisory board, Soistman will help guide the firm's efforts to implement its infectious disease testing technologies. Alameda, California-based Alveo is developing its be.well platform, a point-of-care, at-home diagnostic tool.

Sep 15, 2020

NeoGenomics: Madhushree Ghosh

NeoGenomics announced that Madhushree Ghosh has joined the company as VP of alliances and companion diagnostics. She previously served as the senior director of strategic accounts and global strategic partnerships at Thermo Fisher Scientific. She has also served as VP of alliance management and VP of the research services business unit at Althea Dx, as well as in senior leadership positions at Qiagen and Enigma Diagnostics. Ghosh has expertise in next-generation sequencing, multiplex and real-time PCR, oncology, and infectious diseases.

Sep 14, 2020

Veracyte: Richard Kloos

Veracyte has promoted Richard Kloos to executive medical director, overseeing the company's global medical affairs in all clinical areas addressed by its genomic tests. Kloos previously served as senior medical director of endocrinology at Veracyte, which he joined in 2012. He was previously a professor of endocrinology and metabolism, and nuclear medicine at Ohio State University, and was attending physician at the OSU Comprehensive Care Center. He was also codirector of the OSU Thyroid Cancer Unit and served a four-year term as secretary and chief operating officer for the American Thyroid Association.

Sep 14, 2020

Thermo Fisher Scientific: Joseph Holmes, Peter Hornstra

Joseph Holmes has been elected as VP and chief accounting officer of Thermo Fisher Scientific, effective March 31, 2021. He will succeed Peter Hornstra, who will retire from the company March 31. Holmes is currently senior director of technical accounting at Thermo Fisher, a position he assumed when he joined the company in 2017. Previously, he was director of technical accounting and reporting at St. Jude Medical, which was acquired by Abbott Laboratories in 2017.

Sep 14, 2020

Vizgen: Terry Lo, Peidong Wang

Spatial gene expression analysis startup Vizgen has appointed Terry Lo as president and CEO, effective immediately. He has more than two decades of experience in developing commercialization strategies for life sciences companies, Vizgen said. Lo comes to Vizgen from Akoya Biosciences, where he was president. He has also held executive positions at PerkinElmer, Roche, Hologic, and Bristol-Myers Squibb. Lo has an MBA from the University of Chicago and a masters' degree in microbiology from Virginia Tech.

Interim CEO Peidong Wang will remain at Vizgen as VP of engineering.

Sep 14, 2020

Pacific Biosciences: Susan Kim

Pacific Biosciences has appointed Susan Kim as CFO, effective Sept. 28, 2020. She brings 20 years of senior-level finance and operations experience. Kim most recently served as CFO for App Annie and Katerra. She has also held leadership roles at KLA Corporation, Morgan Stanley, and Advanced Micro Devices. Kim holds MBA and masters of engineering management degrees from Northwestern University.

Sep 14, 2020

GenMark Diagnostics: Brian Mitchell

GenMark Diagnostics said in a filing with the US Securities and Exchange Commission that Brian Mitchell, its senior vice president of operations, is no longer employed by the company.

Sep 11, 2020

Catalog DNA: David Turek

Catalog DNA, a startup pursuing DNA data storage and computing technology, has named David Turek as CTO. He will oversee technical strategy, business development, and collaborations. Turek joins Catalog after 20 years at IBM, where he led commercialization of the Deep Blue supercomputer, which famously defeated chess legend Garry Kasparov in a series of matches held in 1997. Turek was also involved in creating IBM's Roadrunner and Blue Gene supercomputers.

Sep 11, 2020

Invitae: Kimber Lockhart

Invitae has appointed Kimber Lockhart to its board of directors effective Sept. 10. Lockhart has been chief technology officer at technology-enabled primary care organization One Medical since 2015. From 2009 to 2014, she held various engineering leadership positions at Box, an online file sharing service. Lockhart joined Box in 2009, when it acquired Increo Solutions, a document rendering and collaboration technlogy firm she cofounded and led as CEO.  

Sep 10, 2020

Biofidelity: Heiner Dreismann

Biofidelity has appointed Heiner Dreismann as the firm's chairman. Prior to Biofidelity, Dreismann served as president and CEO of Roche Molecular Systems. He currently serves on the board of several public and private life sciences and healthcare firms in the US, Europe, and Israel. 

Sep 10, 2020

Myriad Genetics: Rashmi Kumar

Myriad Genetics' board of directors has elected Rashmi Kumar, senior VP and global chief information officer at Hewlett Packard, as its new member and appointed her to the audit and finance committee. With the election of Kumar, Myriad's board now has 12 members. Kumar previously worked at McKesson Corporation as senior VP, chief information officer, and US pharmaceutical and global chief data officer. 

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.